Threes, while full acquisition would be the CLEANEST approach we must consider that PPHM went to lengths to separate the Avid CDMO business from the PPHM R&D and cut down on R&D expenses.
So a BUY-OUT might have been in the plans. The buy-out is the ONLY WAY to steel our involvement in further profits of PS-Targeting R&D away in that the new owner might not even be listed.
With an acquisition that is also possible (cash acquisition) but listed companies will want to include shares. Form a negotiation point of view SHARES limit their risk because the vendors remains part of the risk carriers and that compensate dilution of their existing shareholders and justifies a different immediate cash part that can be lower.
You are correct Bavtuximab, Cotara, Biomarkers and Imaging PNG's should be sold. Betabodies, I suspect them to be uderlying the long term protected technique for Exosomes and Avid's 'all targets' platform. In that case they should be kept and and possibly licensed for non-diagnostic purposed to BP.
But indeed we do not know what depends on what and in order to take shareholder votes on such topics as acquisitions, mergers, partial buy-outs, etc we need to be FULLY INFORMED of what we HAVE and what we SELL or KEEP and what they means for FUTURE leveraging/profits for us shareholders.
We do not want to have to expand Avid factories, take the exploitation risks and market fluctuations while having to pay most of our margin to licenses on IP we owned to begin with.
So no IP SELL and License Back operation to take the cream of our investment!
AIMO
Market Data 
Markets 
AI
